A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders. The Company was incorporated in Delaware, commenced operations in 2005, became publicly traded in 2012, and is listed on the NASDAQ Stock Exchange under the ticker symbol SUPN. Our principal executive offices are located in Rockville, Maryland.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 719M | 719M | 662M | 608M | 667M | 580M |
| Net Income | -39M | -39M | 74M | 1.3M | 64M | 53M |
| EPS | $-0.68 | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
| Free Cash Flow | 46M | 46M | 171M | 111M | 116M | 127M |
| ROIC | -5.1% | -3.7% | 6.4% | 0.1% | 5.3% | 7.9% |
| Gross Margin | 89.6% | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% |
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.15 | 0.50 | 0.52 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -62M | -62M | 82M | -5.3M | 46M | 86M |
| Operating Margin | -8.7% | -8.7% | 12.3% | -0.9% | 6.9% | 14.8% |
| ROE | -3.6% | -3.7% | 7.5% | 0.1% | 7.6% | 6.8% |
| Shares Outstanding | 57M | 57M | 56M | 66M | 62M | 55M |
SUPERNUS PHARMACEUTICALS, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 62.7x vs a median of 15.6x. The company's 5-year average ROIC is 3.2% with a gross margin of 87.6%. At current prices, the estimated annualized return to fair value is -4.1%.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a 5-year average return on invested capital (ROIC) of 3.2%. This is below average and may indicate limited pricing power.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a market capitalization of $2.8B. It is classified as a mid-cap stock.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) does not currently pay a regular dividend.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported annual revenue of $719 million in its most recent fiscal year, based on SEC EDGAR filings.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a net profit margin of -5.4%. The company is currently unprofitable.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) generated $46 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported earnings per share (EPS) of $-0.68 in its most recent fiscal year.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a return on equity (ROE) of -3.7%. A negative ROE may indicate losses or negative equity.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a 5-year average gross margin of 87.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for SUPERNUS PHARMACEUTICALS, INC. (SUPN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a book value per share of $18.73, based on its most recent annual SEC filing.